Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b single-dose BIVV020 study in adults with cold agglutinin disease
NL-OMON55174Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of riliprubart in cold agglutinin disease (CAD), sponsored by Sanofi. Primary endpoints: Safety and tolerability, Clinical laboratory safety and 2 more. Started Feb 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NL-OMON55174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55174.